Tuesday, November 2, 2021

ShapeTX claims breakthrough in tissue-specific gene therapies


Shape Therapeutics has unveiled a capsid discovery platform designed to improve the delivery and safety of gene therapies. The platform is designed to generate adeno-associated virus (AAV) vectors that home in on specific tissues, thereby enabling gene therapy developers to achieve the desired effect without causing intolerable toxicity.

Gene therapy developers have run into safety and tolerability issues as they have moved beyond the contained environment of the eye and targeted diseases that affect other organs. Moving from local to systemic delivery has forced researchers to administer larger doses. Some research suggests high doses of AAV vectors can directly damage liver cells and cause inflammation. Other studies have seen adverse events in patients due to the immune response against the AAV vector.

Sponsored by Clinical Ink

Deploy Configurable, Fit-for-Purpose ePRO Solutions, Fast.

Clinical Ink’s enhanced Lunexis™ ePRO+ module streamlines processes through a flexible, unified platform that allows patients and sites a high degree of optionality.

The experience has created an interest in better ways of getting genes into patients. ShapeTX, which raised a $35.5 million series A round last year, presented its answer to the problem at the 2nd RNA Editing Summit. 

Seattle-based ShapeTX is pitching its AAVid platform as the solution. According to the biotech, the platform screens libraries of more than 1 billion unique AAV capsids, compared to the tens of thousands to millions of variants probed by other research groups. The platform combines DNA synthesis, synthetic biology, next-generation sequence barcoding and machine learning algorithms.

“The vast structural space for exploration at the AAV capsid/target cell interface necessitates enormous library size and diversity, which until now, has only been probed with capsid library sizes in the tens of thousands to millions. At ShapeTX, we set out to create a superior AAV capsid discovery platform with library sizes in the billions of unique variants, thereby maximizing the opportunity for novel virus/target cell interactions,” David Huss, head of research at ShapeTX, said in a statement.

If ShapeTX is right, the combination of those technologies will enable it to identify variants that are easy to manufacture and tissue specific. Selecting vectors that zero in on target tissues could enable the use of lower, and by extension potentially safer, doses.

So far, ShapeTX has identified liver-tropic AAV5 variants. Many AAV vectors exhibit liver tropism, but researchers have identified a need to enhance those innate properties if gene therapies are to be used to treat many diseases that affect the organ. ShapeTX is seeking to position AAVid as the answer to that need while also working to apply the platform to other organs.

The startup is far from the first company to pitch itself as a provider of capsids with superior specificity. Companies including Asklepios BioPharmaceutical—which Bayer is buying for $2 billion upfront—and Sirion Biotech have made similar pitches. ShapeTX has solid credentials, though, with George Church, Ph.D., James Collins, Ph.D., and Don Cleveland, Ph.D., joining its scientific advisory board last year. 



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...